Identification of putative biomarkers for the serodiagnosis of drug-resistant Mycobacterium tuberculosis

Proteome Science

Honghai Wang³  Xuelian Zhang³  ZhenLing Cui²  Wenxi Xu³  Ying Xu³  Jun Yue²  Jie Wang²  Yanyan Liu³  Wenjie Wang³  Qingzhong Wang¹  Lu Zhang³ 

[1] Shanghai Centre for Clinical Laboratory, 200126 Shanghai, Peoples Republic of China;Shanghai Pulmonary Hospital, Tongji University, 200433 Shanghai, Peoples Republic of China;State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, 220 Handan Road, 200433 Shanghai, Peoples Republic of China

关键词: Serodiagnosis;    Drug-resistance;    Mycobacterium tuberculosis;    Immunoproteomics;   

Others  :  817527
DOI  :  10.1186/1477-5956-10-12

 received in 2011-08-27, accepted in 2012-02-25,  发布年份 2012

【 摘 要 】

Background

Early diagnosis and treatment of Mycobacterium tuberculosis infection can prevent most deaths resulting from this pathogen; however, multidrug-resistant strains present serious threats to global tuberculosis control and prevention efforts. In this study, we identified antigens that could be used for the serodiagnosis of drug-resistant M. tuberculosis strains, using a proteomics-based analysis.

Results

Serum from patients infected with drug-resistant or drug-susceptible M. tuberculosis strains and healthy controls was subjected to two-dimensional gel electrophoresis using a western blot approach. This procedure identified nine immunoreactive proteins, which were subjected to MALDI-TOF-MS analysis. Six recombinant proteins, namely rRv2031c, rRv0444c, rRv2145c, rRv3692, rRv0859c, and rRv3040, were expressed and used to determine the immuno-reactivity of 100 serum samples. Antibody reactivity against rRv2031c, rRv3692, and rRv0444c was consistently observed. Among them, the best sensitivity and specificity of rRv3692 were 37% and 95% respectively. Furthermore, when rRv2031c and rRv3692 or rRv2031c, rRv3692, and rRv0444c were combined in 2:1 or equal amounts, the assay sensitivity and specificity were improved to 56.7% and 100% respectively.

Conclusions

These results suggest that Rv2031c, Rv3692, and Rv0444c are possible candidate biomarkers for effective use in the serodiagnosis of drug-resistant tuberculosis infections, and a combined formula of these antigens should be considered when designing a subunit assay kit.

【 授权许可】

   
2012 Zhang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]WHO: Guidelines for surveillance of drug resistance in tuberculosis (document WHO/HTM/TB/2009.422). Geneva: World Health Organization; 2009.
• [2]WHO: Anti-tuberculosis drug resistance in the world. Third global report. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance(WHO/CDC/TB/2004). Geneva: World Health Organization; 2004.
• [3]Dorman SE, Chaisson RE: From magic bullets back to the Magic Mountain: the rise of extensively drug-resistant tuberculosis. Nat Med 2007, 13:295-298.
• [4]Agranoff D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, Loosemore A, Tarelli E, Sheldon J, Schwenk A, Pollok R, Rayner CFJ, Krishna S: Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006, 368:1012-1021.
• [5]Marris E: From TB tests, just a 'yes or no' answer, please. Nat Med 2007, 13:267.
• [6]Lyashchenko KR, Colangele M, Houde HA, Jahadali D, Menizies GML: Heterogenous antibody responses in tuberculosis. Infect Immun 1998, 66:3936-3940.
• [7]Abebe F, Holm-Hansen C, Wiker HG, Bjune G: Progress in Serodiagnosis of Mycobacterium tuberculosisInfection. Scand J Immunol 2007, 66:176-191.
• [8]Starck J, Kallenius G, Marklund BI, Andersson DI, Akerlund T: Comparative proteome analysis of Mycobacterium tuberculosi grown under aerobic and anaerobic conditions. Microbiol 2004, 50:821-3829.
• [9]Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K: Evaluation of a nutrient starvation model of Mycobacterium tuberculosi persistence by gene and protein expression profiling. Mol Microbiol 2002, 43:717-731.
• [10]Jungblut PR, Schaible UE, Mollenkopf HJ, Zimny-Arndt U, Raupach B, Mattow J, Halada P, Lamer S, Kaufmann SHE: Comparative proteome analysis of Mycobacterium tuberculosi and Mycobacterium bovi BCG strains: towards functional genomics of microbial pathogens. Mol Microbiol 1999, 33:1103-1117.
• [11]Mattow J, Jungblut PR, Schaible UE, Mollenkopf HJ, Lamer S, Zimny-Arndt U, Hagens K, Müller EC, Kaufmann SHE: Identification of proteins from Mycobacterium tuberculosi missing in attenuated Mycobacterium bovi BCG strains. Electrophoresis 2001, 22:2936-2946.
• [12]Mawuenyega KG, Forst CV, Dobos KM, Belisle JT, Chen J, Bradbury EM, Bradbury ARM, Chen X: Mycobacterium tuberculosis Functional Network Analysis by Global Subcellular Protein Profiling. Mol Biol Cell 2005, 16:396-404.
• [13]Mattow J, Schaible UE, Schmidt F, Hagens K, Siejak F, Brestrich G, Haeselbarth G, Müller EC, Jungblut PR, Kaufmann SHE: Comparative proteome analysis of culture supernatant proteins from virulent Mycobacterium tuberculosis H37Rv and attenuated M-bovi BCG Copenhagen. Electrophoresis 2003, 24:3405-3420.
• [14]Pheiffer C, Betts JC, Flynn HR, Lukey PT, van Helden P: Protein expression by a Beijing strain differs from that of another clinical isolate and Mycobacterium tuberculosis H37Rv. Microbiology 2005, 151:1139-1150.
• [15]Mattow J, Siejak F, Hagens K, Becher D, Albrecht D, Krah A, Schmidt F, Jungblut PR, Kaufmann SHE, Schaible UE: Proteins unique to intraphagosomally grown Mycobacterium tuberculosis. Proteomics 2006, 6:2485-2494.
• [16]Sanchez-Campillo M, Bini L, Comanducci M, Raggiaschi R, Marzocchi B, Pallini V, Ratti G: Identification of immunoreactive proteins of Chlamydia trachomatis by Western blot analysis of a two-dimensional electrophoresis map with patient sera. Electrophoresis 1999, 20:2269-2279.
• [17]Jungblut PR: Proteome analysis of bacterial pathogens. Microbes Infect 2001, 3:831-840.
• [18]Tjalsma H, Schaeps MJR, Swinkels WD: Immunoproteomics: From biomarker discovery to diagnostic applications. Proteomics Clin 2008, 2:167-180.
• [19]Bassey EOE, Catty D, Kumararatne DS, Raykundalia C: Candidate antigens for improved serodiagnosis of tuberculosis. Tuber Lung Dis 1996, 77:136-145.
• [20]Samanich KM, Belisle JT, Sonnenberg MG, Keen MA, Zolla-Pazner S, Laal S: Delineation of Human Antibody Responses to Culture Filtrate Antigens of Mycobacterium tuberculosis. J Infect Dis 1998, 178:534-1538.
• [21]Charlet D, Mostowy S, Alexander D, Sit L, Wiker HG, Behr MA: Reduced expression of antigenic proteins MPB70 and MPB83 in Mycobacterium bovis BCG strains due to a start codon mutation in sigK. Mol Microbiol 2005, 56:1302-1313.
• [22]Saïd-Salim B, Mostowy S, Kristof AS, Behr MA: Mutations in Mycobacterium tuberculosis Rv0444c, the gene encoding anti-SigK, explain high level expression of MPB70 and MPB83 in Mycobacterium bovis. Mol Microbiol 2006, 62:1251-1263.
• [23]Preneta R, Papavinasasundaram KG, Cozzone AJ, Duclos B: Autophosphorylation of the 16 kDa and 70 kDa antigens (Hsp 16.3 and Hsp 70) of Mycobacterium tuberculosis. Microbiol 2004, 150:2135-2141.
• [24]Beck ST, Leite OM, Arruda RS, Ferreira AW: Humoral response to low molecular weight antigens of Mycobacterium tuberculosis by tuberculosis patients and contacts. Braz J Med Biol Res 2005, 38:587-596.
• [25]Demissie A, Leyten EM, Abebe M: Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 2006, 13:179-186.
• [26]Kyte J, Doolittle RF: A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982, 157:105-132.
• [27]Zhang M, Yang YP, Xu Y, Qie YQ, Wang JL, Zhu BD, Wang QZ, Jin RL, Xu SF, Wang HH: Trehalose-6-phosphate Phosphatase from Myco bacterium tuberculosis induces humoral and cellular immuneresponses. FEMS Immunol Med Microbiol 2007, 49:68-74.
• [28]Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A: Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010, 75(9729):1920-1937.
• [29]Shreemanta KP, Kaufmann SHE: The quest for biomarkers in tuberculosis. Drug Discov Today 2010, 15(3/4):148-157.
• [30]Pedersen SK, Sloane AJ, Prasad SS, Sebastian LT, Lindner RA, Hsu M, Robinson M, Bye PT, Weinberger RP, Harry JL: An Immunoproteomic approach for identification of clinical biomarkers for monitoring disease. Mol Cell Proteomics 2005, 4:1052-1060.
• [31]Leroy B, Roupie V, Noel-Georis I, Rosseels V, Walravens K, Govaerts M, Huygen K, Wattiez R: Antigen discovery, A postgenomic approach to paratuberculosis diagnosis. Proteomics 2007, 7:1164-1176.
• [32]Ramaswamy SV, Reich R, Dou SJ, Jasperse L, Pan X, Wanger A, Quitugua T, Graviss EA: Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Ch 2003, 47:1241-1250.
• [33]Bahk YY, Kim SA, Kim JS, Euh YJ, Bai GH, Cho SN, Kim YS: Antigens secreted from Mycobacterium tuberculosis: identification by proteomics approach and test for diagnostic marker. Proteomics 2004, 4:1-9.
• [34]Zheng XJ, Hong LL, Shi LX, Guo JQ, Sun Z, Zhou JY: Proteomic analysis of host cells infected with infectious bursal disease virus. Mol Cell Proteomics 2008, 7:612-625.
• [35]Gharahdaghi F, Weinberg CR, Meagher DA, Imai BS, Mische SM: Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: A method for the removal of silver ions to enhance sensitivity. Electrophoresis 1999, 20:601-605.
• [36]Griffin TJ, Gygi SP, Ideker T, Rist B, Eng J, Hood L, Aebersold R: Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol Cell Proteomics 2002, 1:323-333.
• [37]Sambrook J, Fritsch EF, Maniatis T: Molecular Coning: A Laboratory Manual. 2nd edition. New York: Cold Spring Harbor Laboratory Press; 1989.